Legal status in the United States

Is CagriSema legal?

Read at FDA, DEA and WADAPublished by PepVault

CagriSema has no FDA-approved product (it is in phase 3 trials), is not a federally controlled substance, and is not named on WADA’s Prohibited List (from January 1, 2027, its S0 class names peptides in general), as of November 18, 2026.

CagriSema at a glance

CheckStatus, read Nov 18, 2026
FDA approvalNot approved; in phase 3 trials
CompoundingBarred from compounding (FDA)
DEA scheduleNot controlled
Sport (WADA)Not named; from 2027, S0 names peptides in general

FDA approval

CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy).

In clinical trials

Novo Nordisk is testing CagriSema in phase 3 trials: ClinicalTrials.gov lists 9 active phase 3 studies of it, for obesity, type 2 diabetes, heart disease and high blood pressure.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

FDA writes that cagrilintide, one of CagriSema’s two medicines, cannot be used in compounding under federal law.

The source: “Retatrutide and cagrilintide cannot be used in compounding under federal law.”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

Until December 31, 2026: The 2026 Prohibited List doesn’t name cagrilintide, CagriSema or semaglutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name CagriSema, and whether S0 reaches it still turns on its approval outside the United States.

How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

What this means and doesn’t

This page reports what the agencies’ own pages said about CagriSema in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is CagriSema FDA approved?

    CagriSema, cagrilintide combined with semaglutide, has no FDA-approved product: Drugs@FDA lists no application with cagrilintide in it. Semaglutide on its own is approved (Ozempic, Wegovy). Novo Nordisk is testing CagriSema in phase 3 trials: ClinicalTrials.gov lists 9 active phase 3 studies of it, for obesity, type 2 diabetes, heart disease and high blood pressure.

  • Is CagriSema a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is CagriSema banned in sport?

    Until December 31, 2026: The 2026 Prohibited List doesn’t name cagrilintide, CagriSema or semaglutide. S0 bans any substance not covered elsewhere on the list that has “no current approval by any governmental regulatory health authority for human therapeutic use”; whether that reaches it turns on its approval outside the United States, which this page doesn’t cover. From January 1, 2027: WADA’s 2027 list adds “peptides” to S0’s examples of non-approved substances, and its explanatory note says a peptide not named on the list “may still be prohibited”. It still doesn’t name CagriSema, and whether S0 reaches it still turns on its approval outside the United States.

  • What does FDA say about compounding CagriSema?

    FDA writes that cagrilintide, one of CagriSema’s two medicines, cannot be used in compounding under federal law.

  • What does FDA say about the “research use only” label?

    FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo